Infants who presented with pulmonary symptoms when diagnosed with gastroesophageal reflux disease had a higher incidence of early onset asthma compared with infants who did not have pulmonary symptoms.
Adolescents with asthma treated with dupilumab experienced significant improvements in FEV1 compared with placebo.
Patients with moderate to severe persistent allergic asthma who were treated with omalizumab experienced greater improvements in lung function after 16 weeks compared with those treated with placebo.
Montelukast plus levocetirizine demonstrated a significant reduction in mean daytime nasal symptom scores compared with montelukast monotherapy.
Benralizumab was associated with a significant reduction in annual asthma exacerbation rates.
Black and Hispanic respondents with asthma were less likely to use complementary alternative medicine than their white counterparts.
Disrupting regular combination inhaled corticosteroid therapy refills increased hospitalizations and exacerbations.
Regardless of severity, when children's asthma was appropriately managed according to guidelines, they experienced significant improvements.
A higher number of acute respiratory infections before the age of 2 may increase the risk for asthma by age 7.
Lower exposure to Proteobacteria in umbilical cord serum was associated with an increased risk for childhood wheezing.
African-American adolescents with asthma had improved outcomes when they received a comprehensive treatment plan.
The most common error related to the use of metered dose inhalers was the failure to attach the inhaler to a spacer.
The PFS formulation eliminates the need to reconstitute the solution before administration.
For every 10-fold rise in methyl and propyl concentrations, there was a 2.61 and a 2.18 increased prevalence odds ratio, respectively, of reporting an emergency department visit in the last 12 months in boys with asthma.
Smoking cessation in patients with asthma is associated with reduced symptoms, improved lung function and quality of life, reduced use of rescue medications, improved airway hyperresponsiveness, and decreased hyperactivity.
PubMed was searched to obtain data on the relative efficacies of benralizumab, dupilumab, lebrikizumab, mepolizumab, reslizumab, and tralokinumab.
Cockroach and mouse allergies were most often associated with poorly controlled asthma and exacerbations in urban adolescents.
Children of East Asian-born parents had an increased risk for allergic rhinitis and aeroallergen sensitization compared with children of Caucasian ancestry.
Total omega-3 and omega-6 plasma polyunsaturated fatty acids relative abundances were significantly inversely correlated with asthma/recurrent wheeze and allergic sensitization.
Although allergic sensitization and hay fever rates increased as children grew older, the rates of asthma dropped.
Results from the extension trial showed a similar safety and tolerability profile for Fasenra as that seen in SIROCCO and CALIMA.
An increase was seen in asthma hospital visits with increasing ambient particulate matter in San Luis Valley.
The SYGMA trials assessed the use of an as-needed combined corticosteroid/beta-agonist inhaler in patients with mild asthma.
Currently, 3 anti-interleukin (IL)5 pathway-directed treatments (benralizumab, mepolizumab, reslizumab) have been approved by the Food and Drug Administration for the treatment of severe asthma with an eosinophilic phenotype.
In a population of primarily Latino children from low-income households, a program of school-supervised use of once-daily inhaled corticosteroids failed to improve asthma control.
Overall, 5 phenotypes were identified and differentiated mainly by patterns of wheezing and aeroallergen sensitization: low wheeze-low atopy, low wheeze-high atopy, transient wheeze-low atopy, high wheeze-low atopy, and high wheeze-high atopy.
Nasal expression of interleukin-10 showed an association with perceived stress burden, while perceived stress burden was strongly associated with asthma control score.
The designation was based on data from the Phase 2b PATHWAY trial that evaluated 3 doses of tezepelumab as add-on therapy in patients with a history of asthma exacerbations and uncontrolled asthma receiving inhaled corticosteroids/long-acting β-agonist with or without oral corticosteroids and additional asthma controllers vs placebo.
Significant negative correlations were seen between visceral fat area and bronchial lumen diameter and lumen area, and significant positive correlations were seen between subcutaneous fat area and bronchial wall area and total area.
A total of 8% of patients with asthma exacerbations met the criteria for diagnosing anaphylaxis, with 3.4% having likely experienced anaphylaxis.